ArticleBreast cancer research and treatment2015
Impact of adjuvant taxane-based chemotherapy on development of breast cancer-related lymphedema: results from a large prospective cohort.
Article in Breast cancer research and treatment, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07315880 (Extracellular Fluid Changes During Neoadjuvant Chemotherapy in Breast Cancer), which is not on this map. Cited by 49 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Extracellular Fluid Changes During Neoadjuvant Chemotherapy in Breast Cancer: A Prospective Bioimpedance Study
Who cites it
49 citing papers in PubMed, 2 syntheses or guidelines pooled it, 110 citations in OpenAlex.
- Risk factors for long-term arm morbidities following breast cancer treatments: A systematic review.Oncotarget · 2023Pooled it
- The impact of monitoring techniques on progression to chronic breast cancer-related lymphedema: a meta-analysis comparing bioimpedance spectroscopy versus circumferential measurements.Breast cancer research and treatment · 2021Pooled it
- Trial
- Heavy-Load Lifting: Acute Response in Breast Cancer Survivors at Risk for Lymphedema.Medicine and science in sports and exercise · 2018Trial
- Acute effects of taxanes on sub-tissue fluid proportions in patients with breast cancer who underwent taxane-based chemotherapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Breast Cancer-Related Lymphedema (BCRL): Comprehensive Characterization of Patients Seeking Microsurgical Treatment.Annals of surgical oncology · 2026Article
- Effect of taxaneZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026Article
- Impact of chemotherapy on breast cancer-related lymphedema: a retrospective study.Frontiers in oncology · 2026Article
- Effects of resistance exercise on reducing the risk of lower-limb lymphedema after gynecological cancer surgery.Asia-Pacific journal of oncology nursing · 2025Article
- Preliminary Efficacy/Feasibility Study of a Breast Cancer-Related Lymphedema Prospective Screening and Early Intervention Program at the Dana-Farber Brigham Cancer Center.Journal of clinical medicine · 2025Article
- Factors affecting the formation of lymphedema due to breast cancer (Is primary systemic treatment an independent factor in the formation of breast cancer related lymphedema?).Turkish journal of surgery · 2025Article
- Database study of risk factors for breast cancer-related lymphedema: a statistical analysis of 2359 cases over 10 years.Surgery today · 2025Observational
- Racial and Ethnic Differences in Breast Inflammation and Its Association with Lymphedema Risk After Axillary Lymph Node Dissection.Annals of surgical oncology · 2025Article
- Association between chemotherapy and the risk of developing breast cancer-related lymphedema: a nationwide retrospective cohort study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Incidence of lymphedema related to various cancers.Medical oncology (Northwood, London, England) · 2024Review
- Supraclavicular Irradiation Induces Lymphedema in Breast Cancer Patients Treated with Axillary Lymph Node Dissection and Taxane-Containing Chemotherapy.The breast journal · 2024Article
- Factors affecting lymphedema after neoadjuvant chemotherapy and axillary dissection in female breast cancer patients: a retrospective cohort study based on the Chinese population.Frontiers in oncology · 2024Article
- Breast Cancer-Related Lymphedema (BCRL) and Bioimpedance Spectroscopy: Long-Term Follow-Up, Surveillance Recommendations, and Multidisciplinary Risk Factors.Annals of surgical oncology · 2023Article
- The effect of combined risk factors on breast cancer-related lymphedema: a study using decision trees.Breast cancer (Tokyo, Japan) · 2023Observational
- Risk of Lymphedema and Death after Lymph Node Dissection with Neoadjuvant and Adjuvant Treatments in Patients with Breast Cancer: An Eight-Year Nationwide Cohort Study.Healthcare (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
Taxane-based chemotherapy for the treatment of breast cancer is associated with fluid retention in the extremities; however, its association with development of breast cancer-related lymphedema is unclear. We sought to determine if adjuvant taxane-based chemotherapy increased risk of lymphedema or mild swelling of the upper extremity. 1121 patients with unilateral breast cancer were prospectively screened for lymphedema with perometer measurements. Lymphedema was defined as a relative volume change (RVC) of ≥10 % from preoperative baseline. Mild swelling was defined as RVC 5- <10 %. Clinicopathologic characteristics were obtained via medical record review. Kaplan-Meier and Cox proportional hazard analyses were performed to determine lymphedema rates and risk factors. 29 % (324/1121) of patients were treated with adjuvant taxane-based chemotherapy. The 2-year cumulative incidence of lymphedema in the overall cohort was 5.27 %. By multivariate analysis, axillary lymph node dissection (ALND) (p < 0.0001), higher body mass index (p = 0.0007), and older age at surgery (p = 0.04) were significantly associated with increased risk of lymphedema; however, taxane chemotherapy was not significant when compared to no chemotherapy and non-taxane chemotherapy (HR 1.14, p = 0.62; HR 1.56, p = 0.40, respectively). Chemotherapy with docetaxel was significantly associated with mild swelling on multivariate analysis in comparison to both no chemotherapy and non-taxane chemotherapy groups (HR 1.63, p = 0.0098; HR 2.15, p = 0.02, respectively). Patients who receive taxane-based chemotherapy are not at an increased risk of lymphedema compared to patients receiving no chemotherapy or non-taxane adjuvant chemotherapy. Those treated with docetaxel may experience mild swelling, but this does not translate into subsequent lymphedema.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.